{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:01:07Z","timestamp":1787842867041,"version":"build-2784847793"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T00:00:00Z","timestamp":1730764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"DOI":"10.1186\/s12964-024-01915-0","type":"journal-article","created":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T09:04:37Z","timestamp":1730797477000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Atomoxetine suppresses radioresistance in glioblastoma via circATIC\/miR-520d-5p\/Notch2-Hey1 axis"],"prefix":"10.1186","volume":"22","author":[{"given":"Hyun Jeong","family":"Seok","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Yeon","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Incheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Hwa","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,5]]},"reference":[{"issue":"10","key":"1915_CR1","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"1915_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1188\/16.CJON.S1.2-8","volume":"20","author":"ME Davis","year":"2016","unstructured":"Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20(5):1\u201314.","journal-title":"Clin J Oncol Nurs"},{"issue":"3","key":"1915_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1001\/archneur.63.3.337","volume":"63","author":"JW Henson","year":"2006","unstructured":"Henson JW. Treatment of glioblastoma multiforme: a new standard. Arch Neurol. 2006;63(3):337\u201341.","journal-title":"Arch Neurol"},{"issue":"5","key":"1915_CR4","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3322\/caac.21693","volume":"71","author":"KD Miller","year":"2021","unstructured":"Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL, Barnholtz-Sloan JS. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71(5):381\u2013406.","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"1915_CR5","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00401-007-0243-4","volume":"114","author":"DN Louis","year":"2007","unstructured":"Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97\u2013109.","journal-title":"Acta Neuropathol"},{"issue":"6","key":"1915_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/oncsis.2012.12","volume":"1","author":"T Shimura","year":"2012","unstructured":"Shimura T, Noma N, Oikawa T, Ochiai Y, Kakuda S, Kuwahara Y, Takai Y, Takahashi A, Fukumoto M. Activation of the AKT\/cyclin D1\/Cdk4 survival signaling pathway in radioresistant cancer stem cells. Oncogenesis. 2012;1(6):1\u20139.","journal-title":"Oncogenesis"},{"issue":"9","key":"1915_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers12092511","volume":"12","author":"MY Ali","year":"2020","unstructured":"Ali MY, Oliva CR, Noman ASM, Allen BG, Goswami PC, Zakharia Y, Monga V, Spitz DR, Buatti JM, Griguer CE. Radioresistance in glioblastoma and the development of radiosensitizers. Cancers (Basel). 2020;12(9):1\u201330.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1915_CR8","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1093\/neuonc\/noab288","volume":"24","author":"J Gu","year":"2022","unstructured":"Gu J, Mu N, Jia B, Guo Q, Pan L, Zhu M, Zhang W, Zhang K, Li W, Li M. Targeting radiation-tolerant persister cells as a strategy for inhibiting radioresistance and recurrence in glioblastoma. Neuro Oncol. 2022;24(7):1056\u201370.","journal-title":"Neuro Oncol"},{"key":"1915_CR9","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.addr.2016.02.002","volume":"109","author":"M Krause","year":"2017","unstructured":"Krause M, Dubrovska A, Linge A, Baumann M. Cancer stem cells: radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. Adv Drug Deliv Rev. 2017;109:63\u201373.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1915_CR10","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.gendis.2022.12.013","volume":"11","author":"D Ajmeera","year":"2024","unstructured":"Ajmeera D, Ajumeera R. Drug repurposing: a novel strategy to target cancer stem cells and therapeutic resistance. Genes Dis. 2024;11(1):148\u201375.","journal-title":"Genes Dis"},{"issue":"1","key":"1915_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1358\/dnp.2010.23.1.1440373","volume":"23","author":"AI Graul","year":"2010","unstructured":"Graul AI, Sorbera L, Pina P, Tell M, Cruces E, Rosa E, Stringer M, Castaner R, Revel L. The year\u2019s new drugs & biologics - 2009. Drug News Perspect. 2010;23(1):7\u201336.","journal-title":"Drug News Perspect"},{"issue":"3","key":"1915_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrd1031","volume":"2","author":"VC Jordan","year":"2003","unstructured":"Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov. 2003;2(3):205\u201313.","journal-title":"Nat Rev Drug Discov"},{"issue":"119527","key":"1915_CR13","first-page":"1","volume":"278","author":"S Sritharan","year":"2021","unstructured":"Sritharan S, Sivalingam N. A comprehensive review on time-tested anticancer drug doxorubicin. Life Sci. 2021;278(119527):1\u201310.","journal-title":"Life Sci"},{"issue":"2","key":"1915_CR14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","volume":"7","author":"H Cortes-Funes","year":"2007","unstructured":"Cortes-Funes H, Coronado C. Role of anthracyclines in the era of targeted therapy. Cardiovasc Toxicol. 2007;7(2):56\u201360.","journal-title":"Cardiovasc Toxicol"},{"key":"1915_CR15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.semcancer.2019.09.012","volume":"68","author":"S Aggarwal","year":"2021","unstructured":"Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: old weapon for new battle. Semin Cancer Biol. 2021;68:8\u201320.","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"1915_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-21330-0","volume":"12","author":"S Rodriguez","year":"2021","unstructured":"Rodriguez S, Hug C, Todorov P, Moret N, Boswell SA, Evans K, Zhou G, Johnson NT, Hyman BT, Sorger PK, et al. Machine learning identifies candidates for drug repurposing in Alzheimer\u2019s disease. Nat Commun. 2021;12(1):1\u201313.","journal-title":"Nat Commun"},{"issue":"1","key":"1915_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-27420-x","volume":"13","author":"S Parolo","year":"2023","unstructured":"Parolo S, Mariotti F, Bora P, Carboni L, Domenici E. Single-cell-led drug repurposing for Alzheimer\u2019s disease. Sci Rep. 2023;13(1):1\u201314.","journal-title":"Sci Rep"},{"issue":"1","key":"1915_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-14721-w","volume":"12","author":"C Tomi-Andrino","year":"2022","unstructured":"Tomi-Andrino C, Pandele A, Winzer K, King J, Rahman R, Kim DH. Metabolic modeling-based drug repurposing in glioblastoma. Sci Rep. 2022;12(1):1\u201313.","journal-title":"Sci Rep"},{"issue":"13","key":"1915_CR19","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","volume":"390","author":"WG Meissner","year":"2024","unstructured":"Meissner WG, Remy P, Giordana C, Maltete D, Derkinderen P, Houeto JL, Anheim M, Benatru I, Boraud T, Brefel-Courbon C, et al. Trial of lixisenatide in early Parkinson\u2019s disease. N Engl J Med. 2024;390(13):1176\u201385.","journal-title":"N Engl J Med"},{"issue":"2","key":"1915_CR20","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0006-3223(02)01671-2","volume":"53","author":"D Michelson","year":"2003","unstructured":"Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112\u201320.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"1915_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-019-49609-9","volume":"9","author":"JC Corona","year":"2019","unstructured":"Corona JC, Carreon-Trujillo S, Gonzalez-Perez R, Gomez-Bautista D, Vazquez-Gonzalez D, Salazar-Garcia M. Atomoxetine produces oxidative stress and alters mitochondrial function in human neuron-like cells. Sci Rep. 2019;9(1):1\u20139.","journal-title":"Sci Rep"},{"issue":"21","key":"1915_CR22","doi-asserted-by":"publisher","first-page":"8644","DOI":"10.1073\/pnas.1221478110","volume":"110","author":"P Mao","year":"2013","unstructured":"Mao P, Joshi K, Li J, Kim SH, Li P, Santana-Santos L, Luthra S, Chandran UR, Benos PV, Smith L, et al. Mesenchymal glioma stem cells are maintained by activated glycolytic metabolism involving aldehyde dehydrogenase 1A3. Proc Natl Acad Sci U S A. 2013;110(21):8644\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1915_CR23","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.omtn.2019.05.022","volume":"17","author":"S Kim","year":"2019","unstructured":"Kim S, Choi JY, Seok HJ, Park MJ, Chung HY, Bae IH. miR-340-5p suppresses aggressiveness in glioblastoma multiforme by targeting Bcl-w and Sox2. Mol Ther Nucleic Acids. 2019;17:245\u201355.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"5","key":"1915_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pbio.1002152","volume":"13","author":"J Yin","year":"2015","unstructured":"Yin J, Park G, Kim TH, Hong JH, Kim YJ, Jin X, Kang S, Jung JE, Kim JY, Yun H, et al. Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII promotes self-renewal and tumor progression of glioma stem cells. PLoS Biol. 2015;13(5):1\u201325.","journal-title":"PLoS Biol"},{"issue":"7","key":"1915_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1111\/1759-7714.14326","volume":"13","author":"K Zhang","year":"2022","unstructured":"Zhang K, Fan R, Zhao D, Liu P, Yang Z, Liu J, Zhang S, Rao S, Wang Y, Wan L. CircATIC inhibits esophageal carcinoma progression and promotes radiosensitivity by elevating RHCG through sponging miR-10-3p. Thorac Cancer. 2022;13(7):934\u201346.","journal-title":"Thorac Cancer"},{"issue":"1","key":"1915_CR26","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ncrna.2023.10.012","volume":"9","author":"HJ Seok","year":"2024","unstructured":"Seok HJ, Choi JY, Lee DH, Yi JM, Lee HJ, Bae IH. miR-765 as a promising biomarker for low-dose radiation-induced pulmonary fibrosis. Noncoding RNA Res. 2024;9(1):33\u201343.","journal-title":"Noncoding RNA Res"},{"issue":"7","key":"1915_CR27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.7150\/ijbs.41246","volume":"16","author":"L Bian","year":"2020","unstructured":"Bian L, Meng Y, Zhang M, Guo Z, Liu F, Zhang W, Ke X, Su Y, Wang M, Yao Y, et al. ATM expression is elevated in established radiation-resistant breast cancer cells and improves DNA repair efficiency. Int J Biol Sci. 2020;16(7):1096\u2013106.","journal-title":"Int J Biol Sci"},{"issue":"10","key":"1915_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells7100147","volume":"7","author":"F Danielsson","year":"2018","unstructured":"Danielsson F, Peterson MK, Caldeira Araujo H, Lautenschlager F, Gad AKB. Vimentin diversity in health and disease. Cells. 2018;7(10):1\u201338.","journal-title":"Cells."},{"issue":"19","key":"1915_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13194985","volume":"13","author":"S Usman","year":"2021","unstructured":"Usman S, Waseem NH, Nguyen TKN, Mohsin S, Jamal A, Teh MT, Waseem A. Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis. Cancers (Basel). 2021;13(19):1\u201326.","journal-title":"Cancers (Basel)"},{"key":"1915_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.canlet.2021.07.041","volume":"520","author":"N Zhang","year":"2021","unstructured":"Zhang N, Hua X, Tu H, Li J, Zhang Z, Max C. Isorhapontigenin (ISO) inhibits EMT through FOXO3A\/METTL14\/VIMENTIN pathway in bladder cancer cells. Cancer Lett. 2021;520:400\u20138.","journal-title":"Cancer Lett"},{"issue":"1","key":"1915_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-023-01668-1","volume":"9","author":"Q Shi","year":"2024","unstructured":"Shi Q, Xue C, Zeng Y, Yuan X, Chu Q, Jiang S, Wang J, Zhang Y, Zhu D, Li L. Notch signaling pathway in cancer: from mechanistic insights to targeted therapies. Signal Transduct Target Ther. 2024;9(1):1\u201337.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1915_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers11030292","volume":"11","author":"R Bazzoni","year":"2019","unstructured":"Bazzoni R, Bentivegna A. Role of notch signaling pathway in glioblastoma pathogenesis. Cancers (Basel). 2019;11(3):1\u201325.","journal-title":"Cancers (Basel)"},{"key":"1915_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2021.105780","volume":"171","author":"W Wu","year":"2021","unstructured":"Wu W, Klockow JL, Zhang M, Lafortune F, Chang E, Jin L, Wu Y, Daldrup-Link HE. Glioblastoma multiforme (GBM): An overview of current therapies and mechanisms of resistance. Pharmacol Res. 2021;171:1\u201326.","journal-title":"Pharmacol Res"},{"issue":"1","key":"1915_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-021-02201-4","volume":"41","author":"D Chen","year":"2022","unstructured":"Chen D, Chou FJ, Chen Y, Huang CP, Tian H, Wang Y, Niu Y, You B, Yeh S, Xing N, Chang C. Targeting the radiation-induced ARv7-mediated circNHS\/miR-512-5p\/XRCC5 signaling with Quercetin increases prostate cancer radiosensitivity. J Exp Clin Cancer Res. 2022;41(1):1\u201312.","journal-title":"J Exp Clin Cancer Res"},{"key":"1915_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fddsv.2023.1201419","volume":"3","author":"N Singh","year":"2023","unstructured":"Singh N, Vayer P, Tanwar S, Poyet J-L, Tsaioun K, Villoutreix BO. Drug discovery and development: introduction to the general public and patient groups. Frontiers in Drug Discovery. 2023;3:1\u201311.","journal-title":"Frontiers in Drug Discovery"},{"issue":"5","key":"1915_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jama.2020.8648","volume":"324","author":"JA DiMasi","year":"2020","unstructured":"DiMasi JA. research and development costs of new drugs. JAMA. 2020;324(5):1\u201311.","journal-title":"JAMA"},{"issue":"19","key":"1915_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms231911455","volume":"23","author":"V Parvathaneni","year":"2022","unstructured":"Parvathaneni V, Chilamakuri R, Kulkarni NS, Baig NF, Agarwal S, Gupta V. Exploring amodiaquine\u2019s repurposing potential in breast cancer treatment-assessment of in-vitro efficacy & mechanism of action. Int J Mol Sci. 2022;23(19):1\u201321.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"1915_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms232113276","volume":"23","author":"YL Ni","year":"2022","unstructured":"Ni YL, Chien PJ, Hsieh HC, Shen HT, Lee HT, Chen SM, Chang WW. Disulfiram\/copper suppresses cancer stem cell activity in differentiated thyroid cancer cells by inhibiting BMI1 expression. Int J Mol Sci. 2022;23(21):1\u201314.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"1915_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms23073631","volume":"23","author":"H Branco","year":"2022","unstructured":"Branco H, Oliveira J, Antunes C, Santos LL, Vasconcelos MH, Xavier CPR. Pirfenidone sensitizes NCI-H460 non-small cell lung cancer cells to paclitaxel and to a combination of paclitaxel with carboplatin. Int J Mol Sci. 2022;23(7):1\u201316.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1915_CR40","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.15252\/emmm.201302627","volume":"6","author":"SK Carlsson","year":"2014","unstructured":"Carlsson SK, Brothers SP, Wahlestedt C. Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med. 2014;6(11):1359\u201370.","journal-title":"EMBO Mol Med"},{"issue":"1","key":"1915_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.heliyon.2023.e12916","volume":"9","author":"Q Zhou","year":"2023","unstructured":"Zhou Q, Lei C, Cui F, Chen H, Cao X. Circ-ATIC regulates esophageal squamous cell carcinoma growth and metastasis through miR-1294\/PBX3 pathway. Heliyon. 2023;9(1):1\u201313.","journal-title":"Heliyon"},{"issue":"5","key":"1915_CR42","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1007\/s10528-021-10167-3","volume":"60","author":"B Zhang","year":"2022","unstructured":"Zhang B, Chu W, Li Z, Zhang Y, Zhen Q, Lv B, Liu J, Lu C, Zhao X. Circ-ATIC Serves as a sponge of miR-326 to accelerate esophageal squamous cell carcinoma progression by targeting ID1. Biochem Genet. 2022;60(5):1585\u2013600.","journal-title":"Biochem Genet"},{"issue":"6","key":"1915_CR43","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1007\/s10528-022-10228-1","volume":"60","author":"B Wu","year":"2022","unstructured":"Wu B, Wang F, Wang Y, Deng X, Wu W. CircATIC contributes to multiple myeloma progression via miR-324-5p-dependent regulation of HGF. Biochem Genet. 2022;60(6):2515\u201332.","journal-title":"Biochem Genet"},{"issue":"9","key":"1915_CR44","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.7150\/ijbs.96671","volume":"20","author":"C Huang","year":"2024","unstructured":"Huang C, Yang Y, Wang X, Chen S, Liu Z, Li Z, Tang X, Zhang Q. PTBP1-mediated biogenesis of circATIC promotes progression and cisplatin resistance of bladder cancer. Int J Biol Sci. 2024;20(9):3570\u201389.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"1915_CR45","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/neuonc\/nov164","volume":"18","author":"RK Oberoi","year":"2016","unstructured":"Oberoi RK, Parrish KE, Sio TT, Mittapalli RK, Elmquist WF, Sarkaria JN. Strategies to improve delivery of anticancer drugs across the blood-brain barrier to treat glioblastoma. Neuro Oncol. 2016;18(1):27\u201336.","journal-title":"Neuro Oncol"},{"issue":"6","key":"1915_CR46","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/bcp.12881","volume":"81","author":"P Sminia","year":"2016","unstructured":"Sminia P, Westerman BA. Blood-brain barrier crossing and breakthroughs in glioblastoma therapy. Br J Clin Pharmacol. 2016;81(6):1018\u201320.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"1915_CR47","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s00401-003-0810-2","volume":"107","author":"SW Schneider","year":"2004","unstructured":"Schneider SW, Ludwig T, Tatenhorst L, Braune S, Oberleithner H, Senner V, Paulus W. Glioblastoma cells release factors that disrupt blood-brain barrier features. Acta Neuropathol. 2004;107(3):272\u20136.","journal-title":"Acta Neuropathol"},{"issue":"10","key":"1915_CR48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/ijms19102879","volume":"19","author":"M Da Ros","year":"2018","unstructured":"Da Ros M, De Gregorio V, Iorio AL, Giunti L, Guidi M, de Martino M, Genitori L, Sardi I. Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier. Int J Mol Sci. 2018;19(10):1\u201323.","journal-title":"Int J Mol Sci"},{"key":"1915_CR49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2015.02.002","volume":"19","author":"O van Tellingen","year":"2015","unstructured":"van Tellingen O, Yetkin-Arik B, de Gooijer MC, Wesseling P, Wurdinger T, de Vries HE. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment. Drug Resist Updat. 2015;19:1\u201312.","journal-title":"Drug Resist Updat"},{"key":"1915_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bioorg.2020.104435","volume":"105","author":"F Gur","year":"2020","unstructured":"Gur F, Gur B, Erkayman B, Halici Z, Karakoc A. Investigation of serum and brain superoxide dismutase levels depending on atomoxetine used in attention-deficit\/hyperactivity disorder treatment: a combination of in vivo and molecular docking studies. Bioorg Chem. 2020;105:1\u20137.","journal-title":"Bioorg Chem"},{"key":"1915_CR51","first-page":"1","volume":"12","author":"D Fu","year":"2021","unstructured":"Fu D, Wu DD, Guo HL, Hu YH, Xia Y, Ji X, Fang WR, Li YM, Xu J, Chen F, Liu QQ. The mechanism, clinical efficacy, safety, and dosage regimen of atomoxetine for ADHD therapy in children: a narrative review. Front Psychiatry. 2021;12:1\u20137.","journal-title":"Front Psychiatry"},{"issue":"5","key":"1915_CR52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0893-133X(02)00346-9","volume":"27","author":"FP Bymaster","year":"2002","unstructured":"Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit\/hyperactivity disorder. Neuropsychopharmacology. 2002;27(5):699\u2013711.","journal-title":"Neuropsychopharmacology"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01915-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-024-01915-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-024-01915-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T21:15:32Z","timestamp":1730841332000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-024-01915-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,5]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1915"],"URL":"https:\/\/doi.org\/10.1186\/s12964-024-01915-0","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,5]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The clinical data related to this study were approved by the Institutional Review Board (IRB) of the Korea Institute of Radiology and Medical Sciences (KIRAMS) (KIRAMS 2021\u201304-002\u2013001).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"532"}}